OncoMatch/Clinical Trials/NCT06881992
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Is NCT06881992 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Ersodetug for tumor hyperinsulinism (tumor hi).
Treatment: Ersodetug — The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Must have received: anti-hypoglycemic therapy
failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies
Cannot have received: investigational drug or device
Exception: if the treating physician and Medical Monitor consider no significant risk of drug-drug interaction and potential benefit outweighs the risk then the participant may be allowed
Treatment with an investigational drug or device within 30 days or 5 half-lives of the investigational drug (whichever is longer)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Investigative Site · Chicago, Illinois
- Investigative Site · Bethesda, Maryland
- Investigative Site · Boston, Massachusetts
- Investigative Site · Rochester, Minnesota
- Investigative Site · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06881992 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug or device disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify